-
1
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
-
Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
Erdmann, E.4
Massi-Benedetti, M.5
Moules, I.K.6
-
2
-
-
33746588255
-
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
-
(2006)
Diabetes Care
, vol.29
, pp. 1963-1972
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Heine, R.J.4
Holman, R.R.5
Sherwin, R.6
-
3
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
-
(2006)
N Engl J Med
, vol.355
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
Herman, W.H.4
Holman, R.R.5
Jones, N.P.6
-
4
-
-
34250865768
-
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
-
Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 357 (2007) 28-38
-
(2007)
N Engl J Med
, vol.357
, pp. 28-38
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
Gomis, R.4
Hanefeld, M.5
Jones, N.P.6
-
5
-
-
48449106062
-
Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think?
-
Cefalu W.T., and Watson K. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think?. Diabetes 57 (2008) 1163-1165
-
(2008)
Diabetes
, vol.57
, pp. 1163-1165
-
-
Cefalu, W.T.1
Watson, K.2
-
6
-
-
45149118855
-
Intensive glycemic control in the ACCORD and ADVANCE trials
-
Dluhy R.G., and McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358 (2008) 2630-2633
-
(2008)
N Engl J Med
, vol.358
, pp. 2630-2633
-
-
Dluhy, R.G.1
McMahon, G.T.2
-
7
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
8
-
-
34548609993
-
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus
-
Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007) 386-399
-
(2007)
Ann Intern Med
, vol.147
, pp. 386-399
-
-
Bolen, S.1
Feldman, L.2
Vassy, J.3
Wilson, L.4
Yeh, H.C.5
Marinopoulos, S.6
-
9
-
-
45849124593
-
ENHANCE and ACCORD: controversy over surrogate end points
-
Nissen S.E. ENHANCE and ACCORD: controversy over surrogate end points. Curr Cardiol Rep 10 (2008) 159-161
-
(2008)
Curr Cardiol Rep
, vol.10
, pp. 159-161
-
-
Nissen, S.E.1
-
10
-
-
29144502125
-
Glycemic control and cardiovascular disease--should we reassess clinical goals?
-
Cefalu W.T. Glycemic control and cardiovascular disease--should we reassess clinical goals?. N Engl J Med 353 (2005) 2707-2709
-
(2005)
N Engl J Med
, vol.353
, pp. 2707-2709
-
-
Cefalu, W.T.1
-
11
-
-
33846025092
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
-
Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30 (2007) 162-172
-
(2007)
Diabetes Care
, vol.30
, pp. 162-172
-
-
Buse, J.B.1
Ginsberg, H.N.2
Bakris, G.L.3
Clark, N.G.4
Costa, F.5
Eckel, R.6
-
12
-
-
33745661675
-
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
-
Stettler C., Allemann S., Juni P., Cull C.A., Holman R.R., Egger M., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38
-
(2006)
Am Heart J
, vol.152
, pp. 27-38
-
-
Stettler, C.1
Allemann, S.2
Juni, P.3
Cull, C.A.4
Holman, R.R.5
Egger, M.6
-
13
-
-
0035698055
-
The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus
-
Huang E.S., Meigs J.B., and Singer D.E. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111 (2001) 633-642
-
(2001)
Am J Med
, vol.111
, pp. 633-642
-
-
Huang, E.S.1
Meigs, J.B.2
Singer, D.E.3
-
14
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
15
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
16
-
-
34249902025
-
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action
-
Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30 (2007) 1335-1343
-
(2007)
Diabetes Care
, vol.30
, pp. 1335-1343
-
-
Drucker, D.J.1
-
17
-
-
41049110803
-
New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond
-
Inzucchi S.E., and McGuire D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117 (2008) 574-584
-
(2008)
Circulation
, vol.117
, pp. 574-584
-
-
Inzucchi, S.E.1
McGuire, D.K.2
-
18
-
-
0036279228
-
Diagnosis, classification and cathogenesis of diabetes mellitus
-
Conget I. Diagnosis, classification and cathogenesis of diabetes mellitus. Rev Esp Cardiol 55 (2002) 528-535
-
(2002)
Rev Esp Cardiol
, vol.55
, pp. 528-535
-
-
Conget, I.1
|